CASE REPORT

Glanzmann thrombasthenia complicated by frequent myeloproliferative neoplasm-related thromboembolism: thrombosis occurring regardless of αIIbβIII integrin deficiency

Roger E. G. Schutgens | Rolf T. Urbanus

Van Creveldkliniek, University Medical Centre Utrecht, University Utrecht, The Netherlands

Correspondence
Roger E. G. Schutgens, Internist-hematologist, Van Creveldkliniek, University Medical Centre Utrecht, The Netherlands.
Email: r.schutgens@umcutrecht.nl

Abstract
A patient with Glanzmann Thrombasthenia developed recurrent venous thrombosis with a JAK2 positive myeloproliferative neoplasm. This indicates that the platelet αIIbβIII integrin has no role in venous thrombosis. We discuss the other potential mechanisms that are involved. In addition, we describe the successful use of dabigatran in this patient.

Keywords
dabigatran, Glanzmann thrombasthenia, myeloproliferative neoplasm, platelet, venous thrombosis, αIIbβIII integrin

1 | INTRODUCTION

Glanzmann thrombasthenia (GT) is a rare autosomal recessive platelet disorder characterized by a lack of functional integrin αIIbβ3. The clinical phenotype is dominated by an increased mucocutaneous bleeding tendency.1 The occurrence of venous thromboembolism (VTE) in these patients is very rare, but a total of 12 case reports have been published.2,3 The causes in these cases were (flight) travel, inherited thrombophilia, or peripheral catheter insertion.

2 | CASE PRESENTATION

We describe a 74-year-old woman with GT caused by compound heterozygosity for a pathogenic missense mutation (c.1787T>C p.(Ile596Thr)) and a donor splice site mutation (c.2841+1G>T p.(?)) in the ITGA2B gene (Glanzmann thrombasthenia type 1). Her medical history is extensive, and her bleeding score (ISTH-BAT) was 22 in 2016. She suffered from hypertension for several years and smoked 5 cigarettes a day for over 20 years, but stopped smoking in 2011. She has had multiple episodes of mild microcytic anemia since 2014, for which she undergoes regular colonoscopies for surveillance of adenomas. In March 2016, she developed a superficial thrombophlebitis in her right calf after a long car drive, which was treated with 200mg celecoxib once daily for 4 weeks. In April 2016, she had angina pectoris with ischemic abnormalities on the electrocardiogram. An MRI-heart with adenose showed baso-inferoseptal and baso-anterosal perfusion defects. She was treated with statins, metoprolol, and amiodipine, but platelet inhibitors were contraindicated due to her GT. Treatment was successful, and she remains free of cardiac complaints until today. In October 2017, she developed another thrombophlebitis in her left calf, for which treatment with celecoxib for 4 weeks was
started again. In February 2018, after a mild pneumonia, a deep vein thrombosis (DVT) was diagnosed in the right leg, extending from the popliteal vein to the distal external iliac vein. Her blood count at that time showed a mild microcytic anemia (hemoglobin 9.0 g/dL) with normal leukocyte and platelet counts. CT-thorax/abdomen showed no malignancies; antiphospholipid antibodies (lupus anticoagulant, anticardiolipin (IgM and IgG), and anti-beta2-glycoprotein I (IgM and IgG)) were negative. Treatment with 110mg dabigatran twice daily was started for 3 months. Two weeks after stopping dabigatran, an exacerbation of her microcytic anemia was detected that resolved after iron supplementation. In September 2018, a new DVT occurred in the left leg, for which dabigatran was restarted. After 3 months, dabigatran was reduced to once daily 110 mg for long-term use. She experienced no increase in bleeding tendency and is on dabigatran since. A year later, in October 2019, she had higher hemoglobin values than she was used to (hemoglobin 14.7 g/dL), her platelet count, which was always in the normal range, increased to $599 \times 10^9/L$, and a mild leukocytosis developed ($11.9 \times 10^9/L$). A JAK2 mutation was found (c.1849 G>T; p. Val617Phe, allele burden 33%) and the diagnosis of polycythemia vera was made. To prevent further thrombembolic disease, low-dose hydroxyurea treatment (500 mg daily) was started, and her blood count normalized within two weeks. Meanwhile, she showed slight progression of DVT in her leg, after which dabigatran was increased to twice daily 110 mg. A year later, in Dec 2020, she had progression of DVT, after which dabigatran was increased from twice daily 110mg to twice daily 150mg. To date, she is without complaints and tolerates both dabigatran and hydroxyurea very well.

3 | DISCUSSION

The hallmark of myeloproliferative neoplasms MPN is a dysregulation of cellular processes in bone marrow precursors. Thrombosis frequently occurs in MPNs. Well-known risk factors are age and prior thrombosis. In addition, hematocrit, leukocytosis, smoking, and hypertension all independently contribute to thrombotic risk in MPNs, although they are not incorporated in the current thrombotic risk stratification model.

As the key finding in essential thrombocytosis (ET) is thrombocytosis, it is plausible that platelets contribute to thrombotic risk in MPNs. The efficacy of platelet inhibitors for primary prevention of thrombosis in MPNs further supports an important role for platelets in MPN-associated venous thrombosis. Nevertheless, there is no clear correlation between platelet count and thrombotic risk in ET, although there are reports of altered platelet reactivity. This case report clearly demonstrates that platelet aggregation through integrin αIIbβ3 does not contribute to venous thrombosis in MPNs. This is supported by the observation that platelet aggregates are not dominantly present in venous thrombi. Instead, platelets adhere directly either to the activated endothelium or to the adherent leukocytes, forming small heterotypic aggregates. Platelet recruitment to the venous thrombus depends on the interaction between GPIIbα and exposed VWF.

How then, would platelets contribute to thrombosis in MPNs?

The interplay between platelets and the coagulation system in thrombus formation appears to be pivotal. It has been demonstrated that αIIbβ3-deficient platelets aggregate if fibrin is formed allowed. This fibrin-dependent platelet aggregation is thought to be mediated by glycoprotein VI (GPVI). Indeed, GPVI has been identified as a promising antithrombotic target as GPVI deficiency protects against thrombosis while not interfering with normal hemostasis. Activated platelets subsequently provide a surface on which the coagulation reaction can propagate. Moreover, they secrete both activated factor V and polyphosphates, greatly enhancing the coagulation reaction.

Platelet-leukocytes complexes also play a significant role in venous thrombosis. New evidence shows that CTL2 (choline transporter-like protein 2, also known as SLC44A2) on the surface of neutrophils drives neutrophil activation, recruitment, and NETosis in vivo and that CTL2 is directly bound by activated αIIbβ3 integrin on platelets in a flow-dependent manner in vitro. Especially in MPN, exacerbated response to Toll-like receptor stimulation is suggested to promote platelet/leukocyte/endothelial interactions and secretion of inflammatory mediators, reinforcing the thromboinflammatory state. However, the lack of αIIbβ3 integrin in GT suggests that platelet-leukocyte complexes do not play an important role in MPN-related VTE.

In this case, MPN was diagnosed after the occurrence of VTE. Hence, primary prevention was not an issue. However, if we would have found MPN before she developed VTE, we still would not have started antiplatelet therapy, in the assumption that her M. Glanzmann would provide a natural protection against VTE. We decided to treat the VTE with a direct oral anticoagulant (DOAC), as the superiority of DOACs over vitamin K antagonists in terms of safety is demonstrated. We used a dose of 110 mg twice daily, as also recommended by the manufacturer in patients with an increased bleeding risk. Unfortunately, our patient had progression of VTE for which the dose of dabigatran was increased twice. She did not experience any bleeding episodes in 2 years of follow-up. We are not aware of other patients with GT currently treated with a
DOAC. We do like to point out that this is a unique case, where the procoagulant activity is pronounced, perhaps counterbalancing the bleeding risks with a DOAC here.

4 | CONCLUSION

In summary, this case shows that the platelet αIIbβ3 integrin is not involved in the pathogenetic mechanism of relapsing venous thrombosis in MPN. This might argue for further interest in the therapeutic role of GPVI inhibition.

ACKNOWLEDGEMENT

Informed consent was obtained from the patient.

CONFLICT OF INTEREST

RS and RU have no conflicts of interest to declare.

AUTHOR CONTRIBUTIONS

RS and RU both wrote the manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Roger E. G. Schutgens  
https://orcid.org/0000-0002-2762-6033

REFERENCES

1. Perez Botero J, Lee K, Branchford BR, et al. Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica. 2020;105:888-894.
2. Ragsdell B, Thachil J. Lessons from recurrent deep vein thrombosis in Glanzmann thrombasthenia. Haemophilia. 2013;19:e391-393.
3. Girolami A, Sambado L, Bonamigo E, Vettore S, Lombardi AM. Occurrence of thrombosis in congenital thrombocytopenic disorders: a critical annotation of the literature. Blood Coagul Fibrinolysis. 2013;24:18-22.
4. Grinfeld J. Prognostic Models in the Myeloproliferative Neoplasms. Blood Rev. 2020;42:100713.
5. Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012;120:1409-1411.
6. Connor DE, Ma DDF, Joseph JE. Flow cytometry demonstrates differences in platelet reactivity and microparticle formation in subjects with thrombocytopenia or thrombocytosis due to primary haematological disorders. Thromb Res. 2013;132:572-577.
7. Griesshammer M, Beneke H, Nussbaumer B, Grünewald M, Bangert M, Bergmann L. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythemia. Thromb Res. 1996;96:191-196.
8. Cesar JM, de Miguel D, García Avello A, Burgaleta C. Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100. Am J Clin Pathol. 2005;123:772-777.
9. Panova-Noeva M, Marchetti M, Russo L, et al. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. Thromb Res. 2013;132:88-93.
10. Małecki R, Gacka M, Kuliszkiewicz-Janus M, et al. Altered plasma fibrin clot properties in essential thrombocythemia. Platelets. 2015;7104:1-7.
11. Sang Y, Roest M, de Laat B, de Groot PG, Huskens D. Interplay between platelets and coagulation [published online ahead of print 12 Jun 2020]. Blood Rev. 2021;46:100733. https://doi.org/10.1016/j.jbrc.2020.100733
12. Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood. 2004;103:1720-1727.
13. Onselaer MB, Hardy AT, Wilson C, et al. Fibrin and D-dimer bind to monomeric GPVI. Blood Adv. 2017;1:1495-1504.
14. Andrews RK, Arthur JF, Gardiner EE. Targeting GPVI as a novel antithrombotic strategy. J Blood Med. 2014;5:59-68.
15. Kenny M, Schoen I. A handshake between platelets and neutrophils might fuel deep vein thrombosis. Platelets. 2020;31:624-626.
16. Marin Oyarzún CP, Glembotsky AC, Goette NP, et al. Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia. Front Immunol. 2020;11:705.
17. Mai V, Bertoletti L, Cucherat M, et al. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis. PLoS One. 2019;14:e0214134.

How to cite this article: Schutgens REG, Urbanus RT. Glanzmann thrombasthenia complicated by frequent myeloproliferative neoplasm-related thromboembolism: thrombosis occurring regardless of αIIbβIII integrin deficiency. Clin Case Rep. 2021;9:e04757. https://doi.org/10.1002/ccr3.4757